Author: Cyphert Erika L. Wallat Jaqueline D. Pokorski Jonathan K. von Recum Horst A.
Publisher: MDPI
E-ISSN: 2079-6382|6|2|11-11
ISSN: 2079-6382
Source: Antibiotics, Vol.6, Iss.2, 2017-04, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The antibiotic erythromycin has limited efficacy and bioavailability due to its instability and conversion under acidic conditions via an intramolecular dehydration reaction. To improve the stability of erythromycin, several analogs have been developed—such as azithromycin and clarithromycin—which decrease the rate of intramolecular dehydration. We set out to build upon this prior work by developing a conjugate of erythromycin with improved pH stability, bioavailability, and preferential release from a drug delivery system directly at the low pH of an infection site. To develop this new drug conjugate, adamantane-1-carbohydrazide was covalently attached to erythromycin via a pH-degradable hydrazone bond. Since
Related content
Aptamers for Targeted Drug Delivery
By Ray Partha White Rebekah R.
Pharmaceuticals, Vol. 3, Iss. 6, 2010-05 ,pp. :
Trojan Microparticles for Drug Delivery
By Anton Nicolas Jakhmola Anshuman Vandamme Thierry F.
Pharmaceutics, Vol. 4, Iss. 1, 2012-01 ,pp. :
Polysaccharide-Based Micelles for Drug Delivery
By Zhang Nan Wardwell Patricia R. Bader Rebecca A.
Pharmaceutics, Vol. 5, Iss. 2, 2013-05 ,pp. :
Nanotechnology and Drug Delivery: An Update in Oncology
Pharmaceutics, Vol. 3, Iss. 2, 2011-04 ,pp. :